Disruptive Pharma AB
Gunilla Ekström is a seasoned professional with extensive experience in the pharmaceutical and biotech industries. Since May 2022, Gunilla serves as a member of the Board of Directors for Initiator Pharma, and has held similar positions at Disruptive Pharma AB and Strike Pharma AB since June and May 2021, respectively. Gunilla is also the VP of Project Management and co-founder at Gesynta Pharma AB and has been involved as a board member for several companies including CORLINE BIOMEDICAL AB and Emplicure AB since April 2016 and May 2015, respectively. Previously, Gunilla held the role of Managing Director at Ultimovacs AB and CEO at Immuneed. Gunilla's academic credentials include degrees in Biochemistry and an Associate Professorship in Biochemical Toxicology from Karolinska Institutet, coupled with executive finance training from INSEAD.
This person is not in the org chart
This person is not in any teams
Disruptive Pharma AB
Disruptive Pharma is a pharmaceutical company that develops novel drug products by applying a unique drug delivery technology. We develop selected drug products based on our proprietary drug delivery platform, the pharma-grade mesoporous magnesium carbonate (Pharma-MMC). The Disruptive Pharma company has offices in both Uppsala (HQ) and Stockholm. By a clever combination of already approved active pharmaceutical ingredients (APIs) with Pharma-MMC platform, several unique opportunities to realize highly valuable therapeutically equivalent or improved drug products emerges. The Pharma-MMC drug delivery technology can be used to create amorphous solid dispersions of the drug, hence increasing its dissolution and the body’s ability to absorb the drug, and may be used to rescue particularly difficult drugs or to enable novel product formulations Disruptive Pharma is a spin-out from the company Disruptive Materials that is located in Uppsala. The company is well-positioned to exploit its pioneering discovery of a unique mesoporous magnesium carbonate (MMC) material. Up until breakthrough discovery by the group of Professor Maria Strømme in 2012, commercialized by Disruptive Materials AB in 2013.